Beta Bionics (BBNX) Cash & Current Investments (2023 - 2026)

Beta Bionics has reported Cash & Current Investments for 4 years, with the latest figure at $180.5 million in Q2 2026.

• Quarterly Cash & Current Investments fell 27.72% year-over-year to $180.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $180.5 million (down 27.72% YoY) and the FY2025 annual result came in at $219.1 million, up 111.56% from the prior year.
• Cash & Current Investments retreated to $180.5 million in Q2 2026 per BBNX's latest filing, from $199.5 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $249.7 million in Q2 2025 and troughed at $13.0 million in Q2 2024.
• A 4-year average of $142.0 million and a median of $180.5 million in 2026 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2025 and 2026: Cash & Current Investments surged 1816.65% in 2025, then decreased 27.72% in 2026.
• Over 4 years, Cash & Current Investments stood at $96.7 million in 2023, then climbed by 7.06% to $103.6 million in 2024, then jumped by 111.56% to $219.1 million in 2025, then slipped by 17.63% to $180.5 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $180.5 million, $199.5 million, and $219.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.